imidazole coordination raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H24N6O4 | Free tripeptide, without copper |
| Molecular weight | About 340 g/mol | Peptide portion only |
| Appearance | Blue to violet powder | Color from copper coordination |
| Solubility | Soluble in water | pH influences dissolution |
| Common synonyms | Copper tripeptide-1, Cu-GHK | Seen on ingredient labels |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
== Bismuth-213 == Bismuth-213 (213Bi) has a half-life of 45.6 minutes and decays mainly by beta emission to polonium-213; with only 2.1% going via alpha emission to thallium-209; however, as the polonium instantly decays by alpha, one alpha particle is emitted per atom. The amounts needed for medical use are always produced through its decay chain (the neptunium series) from either thorium-229 (limited supply due to the long life of that isotope) or actinium-225, which can be produced directly from radium-226, for example by bombardment with bremsstrahlung photons from a linear particle accelerator, knocking out a neutron and through beta decay giving actinium-225. In 1997, an antibody conjugate with 213Bi was used to treat patients with leukemia, and this isotope has otherwise been used in targeted alpha therapy (TAT) to treat a variety of cancers. Bismuth-213 is also produced in the decay of uranium-233, the fuel bred by thorium reactors, but as mentioned this goes through the long-lived thorium-229, so the production rates from each reactor will not be large.
Instead he believes his work, especially his earlier more autobiographical poems, are rooted in a changing country which echoes the Welshness of the past and the Anglicisation of the new industrial nation: "rural and urban, chapel-going and profane, Welsh and English, Unforgiving and deeply compassionate." Fellow poet and critic Glyn Jones believed that any traces of cynghanedd in Thomas's work were accidental, although he felt Thomas consciously employed one element of Welsh metrics; that of counting syllables per line instead of feet. Constantine Fitzgibbon, who was his first in-depth biographer, wrote "No major English poet has ever been as Welsh as Dylan". Although Thomas had a deep connection with Wales, he disliked Welsh nationalism. He once wrote, "Land of my fathers, and my fathers can keep it". While often attributed to Thomas himself, this line actually comes from the character Owen Morgan-Vaughan, in the screenplay Thomas wrote for the 1948 British melodrama The Three Weird Sisters. Robert Pocock, a friend from the BBC, recalled "I only once heard Dylan express an opinion on Welsh Nationalism. He used three words. Two of them were Welsh Nationalism." Although not expressed as strongly, Glyn Jones believed that he and Thomas's friendship cooled in the later years as he had not 'rejected enough' of the elements that Thomas disliked—"Welsh nationalism and a sort of hill farm morality". Apologetically, in a letter to Keidrych Rhys, editor of the literary magazine Wales, Thomas's father wrote that he was "afraid Dylan isn't much of a Welshman".
== External links == The MEROPS online database for peptidases and their inhibitors: I04.003 Deprecated link archived 2012-12-23 at archive.today SERPINA4+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Jonathan Lavine (1988), business executive, co-managing partner of Bain Capital and chief investment officer of Bain Capital Credit Anita Lo (1988), celebrity chef and restaurateur Danielle Maged (1989), Fox Networks Group executive Joanne Ooi (1989), former creative director of Shanghai Tang; CEO of Clean Air Network and Plukka Paul Greenberg (1990), former CEO of CollegeHumor and current CEO of Nylon Prem Parameswaran (1990), CFO of Eros International Plc and member of the President's Advisory Commission on Asian Americans and Pacific Islanders William von Mueffling (1990), hedge fund manager, president of Cantillon Capital Management Christoph Westphal (1990), biomedical entrepreneur, founder of Alnylam Pharmaceuticals, Acceleron Pharma, and OvaScience Marko Ahtisaari (1991), Finnish entrepreneur; founding CEO of Dopplr; son of Martti Ahtisaari, tenth President of Finland and Nobel Peace Prize laureate Claude Arpels (1991), investor, entrepreneur, grandson of Julien Arpels and heir to the Van Cleef & Arpels fortune Tewodros Ashenafi (1991), founder and CEO of Ethiopian company SouthWest Energy Jack Hidary (1991), financier and entrepreneur, co-founder of the Automotive X Prize and EarthWeb/Dice Inc. E. Javier Loya (1991), CEO of OTC Global Holdings and minority owner in Houston Texans Zia Chishti (1992), entrepreneur and founder of Afiniti and Align Technology Erik Feig (1992), Lionsgate co-president and former president of Summit Entertainment; producer of Step Up series, Escape Plan, Mr. & Mrs.
== Minimum periods of retention == CAP and Clinical Laboratory Improvement Amendments. have written policies for the minimum period of that laboratories should keep laboratory records and materials, with some examples as follows:
Opioid overdose should be reversed as soon as possible. To shorten the time between overdose and naloxone administration, multiple programs have been enacted to improve naloxone access for drug users, caregivers, and first responders. In the US, these efforts include FDA approval of intranasal and injectable naloxone over the counter, professional organizations recommending physicians to co-prescribe naloxone when opioids are used for pain management, free community overdose education and naloxone distribution (OEND) programs, and efforts to train non-medical first responders such as firefighters and police to use naloxone. These actions have reduced opioid-related deaths at the state and national levels and are cost-effective. In the UK, naloxone is a prescription-only medicine, but drug treatment services can supply it without a prescription. In an emergency, anyone can use it as a life-saving measure. In August 2024, a new device was developed by researchers at MIT and Brigham and Women's Hospital that can be implanted under the skin, which rapidly releases naloxone when an overdose is detected.
Sources: en.wikipedia.org
CJD occurs worldwide at roughly 1–1.5 cases per million people per year. Recent surveillance reports indicate a slight increase in recorded incidence in many countries over time. For example, a study made in 2020 noted that sporadic CJD incidence in the U.K. rose from 1990 to 2018, and several other countries also reported increases in CJD cases in the 2000s. On the basis of mortality surveillance from 1979 to 1994, the annual incidence of CJD remained stable at approximately 1 case per million people in the United States. In the United States, CJD deaths among people younger than 30 years of age are extremely rare (fewer than five deaths per billion per year). The disease is found most frequently in people 55–65 years of age, but cases can occur in people older than 90 years and younger than 55 years of age. In more than 85% of cases, the duration of CJD is less than one year (median: four months) after the onset of symptoms. Further information from the CDC:
=== N05AA Phenothiazines with aliphatic side-chain === N05AA01 Chlorpromazine N05AA02 Levomepromazine N05AA03 Promazine N05AA04 Acepromazine N05AA05 Triflupromazine N05AA06 Cyamemazine N05AA07 Chlorproethazine
Guselkumab ( gew-SEL-kew-mab; sold under the brand name Tremfya) is a human monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Diseases of the endocrine glands are common, including conditions such as diabetes mellitus, thyroid disease, and obesity. Endocrine disease is characterized by irregulated hormone release (a productive pituitary adenoma), inappropriate response to signalling (hypothyroidism), lack of a gland (diabetes mellitus type 1, diminished erythropoiesis in chronic kidney failure), or structural enlargement in a critical site such as the thyroid (toxic multinodular goitre). Hypofunction of endocrine glands can occur as a result of the loss of reserve, hyposecretion, agenesis, atrophy, or active destruction. Hyperfunction can occur as a result of hypersecretion, loss of suppression, hyperplastic, or neoplastic change, or hyperstimulation. Endocrinopathies are classified as primary, secondary, or tertiary. Primary endocrine disease inhibits the action of downstream glands. Secondary endocrine disease is indicative of a problem with the pituitary gland. Tertiary endocrine disease is associated with dysfunction of the hypothalamus and its releasing hormones. As the thyroid, and hormones have been implicated in signaling distant tissues to proliferate, for example, the estrogen receptor has been shown to be involved in certain breast cancers. Endocrine, paracrine, and autocrine signaling have all been implicated in proliferation, one of the required steps of oncogenesis. Other common diseases that result from endocrine dysfunction include Addison's disease, Cushing's disease and Grave's disease.
Sources: en.wikipedia.org
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.
The peptide and its copper form have been detected in human plasma, saliva, and urine. Early reports describe levels that fall with age. The functional meaning of these pools is still debated.
Chromatographic separation gives peptide purity, often reported as a percentage. Copper content is checked by a separate elemental method. Moisture and counter-ions may be reported as well.
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.